Primary:- Investigate the feasibility of examining fetal and neonatal brain developmental trajectories in the fetus and neonate with at least one parent with SMI in the mood-psychosis spectrum (vs. parents without SMI) using MRI.- Acquire…
ID
Source
Brief title
Condition
- Other condition
- Manic and bipolar mood disorders and disturbances
Synonym
Health condition
psychische stoornissen: schizofrenie en andere psychotische stoornissen; psychische stoornissen: depressieve stemmingsstoornissen en -afwijkingen
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
Feasibility: The percentage of (future) parents participating in all three
visits using MRI assessments. The study will be considered feasible when >=30%
of invited couples participates in at least one visit including MRI assessment.
Differences between neurodevelopmental trajectories of fetuses/neonates from
parents with vs. without severe mental illness, as measured by:
- Brain volume, cortical folding, cortical thickness, and cortical surface
(global measures and local regions) from T1 and T2 weighted images.
- Fractional anisotrophy (FA), mean diffusivity, axial diffusivity, radial
diffusivity (per fiber and voxel based) from diffusion MRI (dMRI) images.
- Brain activation during resting state (per region and voxel based) from
resting-state fMRI (rs-fMRI) images.
- Graph theory metrics from FA (via dMRI) and rs-fMRI.
- Measurements of fetal growth and development, such as: biparietal diameter
(BPD), transverse cerebellar diameter (TCD), head circumference (HC), thalamus,
femur length (FL), and abdominal circumference (AC), estimated fetal weight,
insula depth, Sylvian fissure depth, and parietal-occipital fissures (POF)
depth, using 2D and 3D fetal ultrasound.
- Doppler fetal hemodynamics, such as: umbilical artery (UA), middle cerebral
artery (MCA), and estimated cerebro-placental ratio (CPR).
Secondary outcome
- Clinical features, i.e. parental psychosis, depression, or mania diagnoses
and symptoms, age of onset parental disorder, number of episodes, number of
hospitalizations, GAF score
- Parental bonding
- Polygenic risk scores for psychiatric traits
- Cortisol levels
- Development of the offspring
Background summary
Severe mental illness, including schizophrenia, bipolar disorder, and major
depressive disorder, contribute significantly to overall disability adjusted
life years. The risk of severe mental illness is especially high for offspring
of parents affected by these disorders* they have a 2-to-3 fold increased risk
to develop psychotic, mood, anxiety, and externalizing disorders. In the
Netherlands, 577.000 children and adolescents are at such high risk (NEMESIS2).
In the US, this number is close to three million. At present, there are
critical knowledge gaps that hamper the implementation of clinical and public
health strategies to alleviate this risk despite the pronounced and obvious
public health ramifications. Accurate detection, diagnosis, and treatment as
early in life as possible is needed. To accomplish this, we propose to
investigate very early brain development, i.e., during the fetal and neonatal
period, which we hypothesize to underlie future onset of severe mental illness.
Given that magnetic resonance imaging (MRI) and ultrasonography are
complementary techniques, using both techniques is essential for complete
evaluation of the fetal brain. Moreover, adding MRI to ultrasound allows us to
examine fetal to neonatal brain growth trajectories in a continuous manner as
ultrasound is no longer possible after birth.
Study objective
Primary:
- Investigate the feasibility of examining fetal and neonatal brain
developmental trajectories in the fetus and neonate with at least one parent
with SMI in the mood-psychosis spectrum (vs. parents without SMI) using MRI.
- Acquire preliminary data to investigate whether differences in brain
developmental trajectories between offspring of parents with and without SMI
can be detected using MRI and ultrasound.
Secondary:
- Investigate how features of fetal and neonatal brain development relate to
clinical features in the affected parent and/or home environment, as well as
parental bonding and offspring development over time.
- Investigate how polygenic risk scores for psychiatric traits and cortical
levels in parents and offspring influence early brain developmental
trajectories in offspring.
Study design
Longitudinal case-control study, family design
Study burden and risks
Study participation involves undergoing an MRI scan of maximally 30 minutes:
two times for the pregnant woman and one time for the neonate. The pregnant
woman will also undergo an ultrasound scan of maximally 30 minutes. For women
who receive obstetric care in the Erasmus MC the visits will be combined as
much as possible with already planned visits (e.g. for antenatal care). To make
the MRI procedure as comfortable as possible for the mother and newborn, we
will use appropriate positioning, and specifically for the newborn swaddling
and timing of feeds, to help optimize effective scanning. We will not use
pharmacological sedation or general anesthesia.
The risks for participation in this study are negligible. The ultrasound
techniques that we will be using are safe and harmless. Worldwide ultrasound is
routine antenatal care. No risks of ultrasound to the mother nor to the fetus
or newborn have been described to date. Moreover, MRI is generally accepted as
safe, both in pregnancy and in neonates, based on extensive experience (Lum &
Tsiouris, 2020; Ray et al., 2016; Tocchio et al., 2015). Therefore, no special
preparation for the subject on top of the Erasmus MC standard procedure is
needed. Both MRI in pregnancy and MRI in neonates have been approved by the
METC in previous studies led by members of the research team [METC protocol ID:
MRI in pregnancy: NL65570.000.18; MRI in neonates: NL67183.078.19].
Participants will experience no direct benefits from our study. In the long
run, increased understanding of the etiology and pathophysiology of mental
disorders on the mood-psychosis spectrum may contribute to diagnosis, early
detection and/or prediction of treatment outcome.
Wytemaweg 8
Rotterdam 3015 CN
NL
Wytemaweg 8
Rotterdam 3015 CN
NL
Listed location countries
Age
Inclusion criteria
All pregnant women and their partners:
• At least 18 years old
• Ability to provide informed consent
• Singleton pregnancy
• Biological parent of the fetus/neonate
Pregnant women and their partners with at least one (future) parent with SMI:
• At least one (future) parent with SMI in the mood-psychosis spectrum
diagnosed before current pregnancy, i.e., schizophrenia, bipolar disorder,
severe MDD (i.e., with high recurrence rate and/or hospitalizations), psychosis
NOS, single psychosis < two years ago (not related to drug use; no postpartum
psychosis after a prior pregnancy)
Neonate:
• Born from parents who participated in visit 1 and/or 2 or born from parents
who would have qualified for inclusion in the study (in other words, families
can also only participate in visit 3).
Exclusion criteria
All pregnant women:
• Contraindication for MRI (including claustrophobia, a cardiac implantable
electronic device, ferromagnetic metal implants, piercing (in some cases),
tattoos (in some cases)) (Ghadimi & Sapra, 2022).
• Postpartum psychosis (after a prior pregnancy)
• Not willing to be informed about incidental findings following MRI assessment
All pregnant women and their partners:
• Substance use disorder (alcohol, drugs), active < six months pre pregnancy as
assessed with R4U or current addiction treatment such as methadone or
buprenorphine
• Not willing to be informed about neonate*s incidental findings following MRI
assessment
All fetuses/neonates:
• Preeclampsia or fetal growth restriction at time of inclusion
• Neurological illness or structural brain abnormalities
• Suspected congenital anomalies or syndromes known to affect neurodevelopment
• Chromosomal abnormalities
• Genetic abnormalities known to impact neurodevelopment
• Premature birth (< 37 weeks)
Pregnant women and their partners without SMI:
• A lifetime diagnosis of SMI in the mood-psychosis spectrum as assessed with
the Mini-International Neuropsychiatric Interview (M.I.N.I.; Sheehan et al.,
1998)
• An SMI in the mood-psychosis spectrum in their first degree relatives
• Use of neurotrophic medication
In all (future) parents, (co)morbidity with other psychiatric diagnoses is not
an exclusion criterion.
Design
Recruitment
Medical products/devices used
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
Register | ID |
---|---|
CCMO | NL83581.000.23 |